Startup Deep Dive : Innovaccer — the healthtech unicorn whose own revenue numbers don’t agree with each other

Innovaccer is a private company that does not publish audited accounts, and its own public statements about its size do not agree with each other. In January 2025, the company told TechCrunch it was “on track” to hit about $250 million in annual recurring revenue that year. Eighteen months later, in July 2026, its chief executive told Fortune the company had “just crossed” $200 million in annual recurring revenue. Both numbers came from Innovaccer itself.

That gap is not a scandal. It is what happens when a company built by two IIT Kharagpur graduates to fix messy, contradictory healthcare data ends up being just as hard to measure from the outside as the hospitals it sells to. Innovaccer has still built one of the more durable healthtech businesses to come out of India-founded entrepreneurship: a $3.45 billion valuation as of January 2025, contracts with seven of the ten largest health systems in the United States, and a 2016 pivot so complete that the founders walked away from paying clients including Disney and NASA to bet the company on a single, unglamorous industry.

Quick facts

What they do

Innovaccer sells software to American healthcare organisations that already run their own electronic health record (EHR) systems — Epic, Oracle Health, Cerner, and dozens of smaller ones — and cannot get those systems to talk to each other or to claims data, pharmacy data and wearables. Its core platform, rebranded Gravity in May 2025, pulls that fragmented information into a single patient record through more than 400 pre-built connectors, then layers analytics and, increasingly, AI agents on top: tools that draft clinical notes, flag patients at risk of readmission, chase prior authorisations and find coding gaps before a claim is denied. As of 2025 the company said it worked with more than 130 healthcare organisations and seven of the ten largest health systems in the United States, including CommonSpirit Health, Kaiser Permanente and Banner Health, unifying records for more than 54 million patients, a figure the company’s own leadership page cites as of 2025.

The origin

The idea did not start in healthcare. Abhinav Shashank and Kanav Hasija met as undergraduates at IIT Kharagpur, and in 2011, while at Wharton and Harvard for a data analytics project, they began working on a way to bring scattered, incompatible datasets together and run analytics across them — a general-purpose data-unification idea, not a healthcare one, according to Innovaccer’s own account of its history. Sandeep Gupta, a graduate of the Indian Institute of Management, Ahmedabad, joined them, and the three incorporated Innovaccer in 2014 in San Francisco. Their early consulting-style data business reportedly counted Disney and NASA among its clients — well-known, well-paying names in totally unrelated industries, as Fortune reported in its account of the company’s founding. The founding insight was narrower than “healthcare”: it was that the same fragmentation problem — data trapped in silos that refuse to reconcile — showed up worst, and mattered most, in hospitals.

The struggle years

The defining crisis came in 2016. Two years after incorporation, with a working data-unification product and clients outside healthcare, the founders chose to abandon the general-purpose business entirely and commit the company to United States healthcare alone — a decision industry accounts describe as a bet-the-company pivot, since it meant walking away from revenue that already existed for a market the founders had never sold into. To learn that market from the inside, the co-founders reportedly spent four months living inside the IT department of Mercy Medical Center in Des Moines, Iowa, studying how a real hospital’s data actually moved (or didn’t), as later reported by Fortune. That immersion led to Innovaccer’s first dedicated healthcare product, a platform called Datashop, launched in 2017 around an early accountable-care-organisation partnership with Mercy.

The company’s second documented crisis was more conventional and came much later. On 24 January 2023, Innovaccer laid off 245 employees, about 15 percent of its workforce at the time, citing what it called an uncertain macroeconomic environment — a round that came after more than a year without new outside funding. It was not the last such round: in May 2026, the company cut 340 more roles as it restructured toward what its CEO called becoming “an AI-native company,” its third layoff round in four years, according to Inc42’s reporting on internal communications at the time.

The turning point

If there is a single moment where Innovaccer’s bet on healthcare stopped looking risky and started looking inevitable, it is the ten months between February and December 2021. In February 2021, a $105 million Series D round, led by B Capital Group and OMERS Growth Equity, pushed the company past $1 billion in valuation for the first time — unicorn status, and proof that the 2016 pivot had worked. Ten months later, on 15 December 2021, Innovaccer raised a further $150 million Series E, led by Mubadala Capital with participation from Tiger Global, Dragoneer and others, at a valuation of $3.2 billion — nearly tripling in under a year, as confirmed by Businesswire’s release of the round and corroborated by Inc42’s and YourStory’s coverage of the same raise. The company’s own telling ties that jump to the pandemic-era acceleration in demand for population-health tools, as US health systems that had spent a decade avoiding investment in data infrastructure suddenly needed it to manage COVID-19 caseloads and, later, value-based-care contracts, at speed.

The money behind it

Innovaccer has raised roughly $675 million across nine rounds since a 2015 seed round, according to Wikipedia’s funding history, TechCrunch’s reporting on the most recent raise, and Entrackr’s coverage of the same deal. The shape of that capital says as much as the total: an early $70 million Series C in February 2020 brought in Tiger Global, Steadview Capital and Dragoneer, giving the company growth-stage credibility before the pandemic-era health-tech boom; the December 2021 Series E brought in Mubadala Capital, a sovereign fund, at the $3.2 billion mark; and the January 2025 Series F — $275 million, roughly a third of it secondary shares letting early seed and Series A investors cash out, per TechCrunch’s reporting — brought in a set of backers that are also customers: Kaiser Permanente, Banner Health and Danaher Ventures, alongside B Capital Group, Generation Investment Management and Microsoft’s M12. That is a notable structural choice: two of Innovaccer’s largest disclosed enterprise clients, Kaiser Permanente and Banner Health, are also equity investors, aligning their incentives with the platform’s success in a way that is unusual outside strategic corporate venture arms. The Series F set the company’s valuation at $3.45 billion, up from the $3.2 billion of December 2021, as reported independently by both TechCrunch and Wikipedia’s funding-round summary, with the FierceHealthcare and Entrackr coverage of the same round in agreement on the $275 million figure.

How it makes money

Innovaccer earns in three layers, and the mix matters more than any single number. The bulk of the money is multi-year SaaS subscription revenue from health systems, payers and, increasingly, life sciences firms, licensing access to the Gravity platform and its applications. Layered on top are per-member-per-month (PMPM) fees, typically reported to fall between $0.50 and $8.00 PMPM depending on the module, tied to population-health and value-based-care contracts where Innovaccer’s tools help a health system or an accountable care organisation manage the cost of a defined group of patients. The third layer is implementation and professional-services revenue, which is real but structurally a cost centre in disguise: every new health system arrives with its own EHR vendor, its own workflows and its own data quirks, so onboarding a large hospital network can take months of custom connector work even with 400-plus pre-built integrations already built.

The margin sits in the subscription layer, once a customer is fully onboarded and connectors are reusable across similar EHR configurations — the same dynamic that makes any horizontal SaaS platform profitable at scale, and unprofitable while it is still building out its integration library. The part people get wrong is assuming Innovaccer is an EHR company, competing directly with Epic or Oracle Health. It is not. It deliberately positions itself as vendor-neutral middleware that sits on top of whatever EHR a hospital already runs, which is both its main pitch — “we don’t ask you to rip out Epic” — and its main long-term vulnerability, discussed under risks below. Innovaccer’s own reporting to federal regulators claims its customers achieved roughly $2.5 billion in aggregate savings in the year to mid-2026, cited in Fortune’s July 2026 profile of the company, a number that functions as its clearest public case for why the PMPM and outcomes-linked fees are worth paying.

The numbers

Innovaccer is a private, US-incorporated company and does not release consolidated, audited financial statements. Two different kinds of numbers exist in public records, and they should not be confused with each other: audited filings for its Indian subsidiary, Innovaccer Analytics Private Limited, registered in Noida and required to file annual accounts with India’s Registrar of Companies; and unaudited, company-reported global annual recurring revenue (ARR) figures given to journalists. The table below keeps both traceable to source and converts the dollar ARR figures to rupees at $1 ≈ ₹96.0 (Trading Economics, 18 September 2026) purely for comparison — the conversion is illustrative, not a restatement of a rupee-denominated result.

The India entity’s FY23 result — Rs 397 crore in revenue and Rs 37 crore in profit, a roughly 9.3 percent net margin — is the only piece of this table that has actually been audited and independently reported, via Entrackr’s coverage of the company’s most recent fundraise. It reflects the Indian subsidiary’s operations (largely engineering and delivery, serving the US parent), not Innovaccer’s global business. The global ARR figures tell a growth story — the company has said it grew revenue roughly 50 percent year-on-year for five straight years, per TechCrunch — but the $250 million “on track” figure given for 2025 and the $200 million “just crossed” figure given eighteen months later for mid-2026 do not sit comfortably together. Innovaccer has not published a reconciliation, and no audited number exists to arbitrate between them; both figures are reported here, attributed to their sources, exactly as the discrepancy stands.

Where the money comes from

Geographically, the split is almost total: essentially all of Innovaccer’s revenue comes from United States healthcare organisations — health systems, payers, government health agencies and, more recently, life sciences companies — even though the company was founded by three Indians and its cost base leans heavily on India. Innovaccer Analytics Private Limited, its Noida-registered subsidiary, reported around 1,201 employees as of April 2026, according to Tracxn, out of a global headcount that Getlatka estimated at roughly 1,700 in 2025 — meaning a large majority of the company’s people sit in India, building and running a product sold entirely into the American market.

By customer type, the company discloses relationships rather than revenue shares: providers (health systems and hospitals) remain its longest-standing and most quoted customer base, with named references including CommonSpirit Health, Kaiser Permanente, Banner Health, Orlando Health and MercyOne. Payers are a newer push, formalised through Galaxy, a dedicated payer-AI platform Innovaccer launched in October 2025. Life sciences and government health agencies are mentioned as expansion targets in the company’s own materials but are not yet broken out with named customers or revenue figures. The surprise, such as it is, is less about the split than about the direction of value: an India-founded, India-staffed company has built and retained ownership of a product that sells into the world’s most expensive and most fragmented healthcare system, rather than executing an outsourced specification for someone else — the reverse of the more familiar Indian IT-services model.

The risks

The first risk is policy dependency. A meaningful share of Innovaccer’s PMPM and outcomes-based revenue is tied to value-based-care and accountable-care-organisation contracts under Medicare’s Shared Savings Program, where the company has publicly reported that its customers achieved a 47 percent year-on-year increase in PMPM savings in the 2024 result year, per a Businesswire release on the company’s own MSSP data. That business model depends on US federal health policy continuing to favour value-based, savings-linked reimbursement over fee-for-service; a material policy reversal would remove the incentive that makes Innovaccer’s outcomes fees worth paying.

The second risk is concentration in a data-security sense rather than a customer-count sense: the company centralises health information for more than 54 million patients on a single platform, by its own leadership page’s count, a scale that makes it an unusually attractive target for a breach and raises the regulatory stakes — under HIPAA in particular — of any single security failure, given how much of its pitch to hospitals rests on being a trustworthy custodian of exactly the data a breach would expose.

The third risk is execution under cost pressure. Innovaccer has now cut staff three times in four years — 245 roles in January 2023 and 340 roles in May 2026, with an unspecified round in between, according to Inc42’s reporting — even as it raised $275 million in fresh capital in January 2025 and completed a roughly Rs 600 crore employee stock buyback only months before the most recent cuts, per the same reporting. Repeated restructuring alongside fresh primary capital and a large buyback is not necessarily a contradiction, but it does suggest a company still working out how much staff its ARR, whatever its true figure, can actually support on the way to the profitability an eventual IPO would require.

The takeaway

The lesson in Innovaccer’s history is not “pick a big market” — every founder already knows that. It is that walking away from working revenue is sometimes the only way to find a defensible one. Shashank, Hasija and Gupta had a general-purpose data business with clients like Disney and NASA in 2016 and chose to give it up for an unproven, regulation-heavy, integration-nightmare of an industry because the same underlying problem — data that refuses to talk to itself — was worth more to solve there than anywhere else. The years that followed were not smooth: four months embedded inside a hospital’s IT department, a near-decade of iteration before consistent 50 percent growth showed up, and three rounds of layoffs even after unicorn status. The takeaway transfers past healthcare: a narrower, harder market where the problem is genuinely acute can be worth more than a broader one where the problem is merely annoying, even when the narrower market punishes you for years before it pays you back.

Frequently asked questions

Is Innovaccer an Indian company or a US company?

Innovaccer Inc. is incorporated and headquartered in San Francisco, California, and sells almost exclusively to US healthcare organisations. It was founded by three Indians — Abhinav Shashank, Kanav Hasija and Sandeep Gupta — and its Indian subsidiary, Innovaccer Analytics Private Limited, based in Noida, employs a large share of its global workforce, as reported by Tracxn.

What is Innovaccer’s current valuation?

Its last disclosed valuation is $3.45 billion, set at its January 2025 Series F round, up from $3.2 billion at its December 2021 Series E round, according to TechCrunch’s and Wikipedia’s coverage of the raise, both corroborated by Entrackr’s reporting.

How much revenue does Innovaccer make?

The company does not publish audited global financials. It has told journalists its global annual recurring revenue was on track for about $250 million in 2025 (TechCrunch, January 2025) but had “just crossed” $200 million by July 2026 (Fortune); its audited Indian subsidiary reported Rs 397 crore in revenue for FY23 (Entrackr).

Is Innovaccer an EHR (electronic health record) system?

No. Innovaccer does not replace a hospital’s EHR, such as Epic or Oracle Health. It is a data and AI layer that sits on top of a health system’s existing EHR, claims and other data sources and unifies them, positioning itself as vendor-neutral rather than as an EHR competitor.

Is Innovaccer planning to go public?

The company has indicated it would consider an IPO once annual recurring revenue reaches roughly $400-500 million, according to TechCrunch’s January 2025 reporting, though as of September 2026 no filing has been made public and the company’s own reported ARR figures for 2025-26 remain below that threshold.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Wikipedia, “Innovaccer” (accessed September 2026)
• TechCrunch, “Innovaccer aims to become healthcare’s AI powerhouse with $275M Series F,” January 2025
• Fortune, “Innovaccer’s CEO walked away from Disney and NASA. Now, the startup has crossed $200 million in ARR,” July 2026
• Businesswire, “Innovaccer Raises $150 Million Series E Round at $3.2 Billion Valuation, Continues Rapid Growth Trajectory,” December 2021
• HIT Consultant, “Innovaccer Raises $150M at $3.2B Valuation to Expand Health Cloud Platform,” December 2021
• Inc42, “Healthtech Unicorn Innovaccer Doubles Valuation To $3.2 Bn With $150 Mn Series E Raise,” December 2021
• YourStory, “[Funding alert] Innovaccer raises $150M at a valuation of $3.2B,” December 2021
• Inc42, “Exclusive: Unicorn Innovaccer Lays Off 340 Employees In Another Restructuring Round,” May 2026
• Entrackr, “Innovaccer lays off 340 employees amid shift to AI-native operations,” May 2026
• Entrackr, “SaaS unicorn Innovaccer raises $275 Mn in Series F round,” January 2025
• Businesswire, “Innovaccer Customers Lead in Clinical Documentation Quality and Care Outcomes Driving 47% PMPM Savings Growth in 2024 MSSP Results,” October 2025
• Getlatka, “Innovaccer Revenue 2025: $252M ARR, $3.5B Valuation” (accessed September 2026)
• Tracxn, “Innovaccer Analytics Private Limited — Company Profile & Financials” (accessed September 2026)
• Forbes India, “Emerging Indian SaaS Leaders: Abhinav Shashank, Kanav Hasija and Sandeep Gupta”
• Innovaccer.com, “Leadership” (accessed September 2026)
• Innovaccer.com, “Innovaccer Raises $150 Million Series E Round at $3.2 Billion Valuation” (company release, December 2021)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.